Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.51 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27505731 | 1.00 | FAAH (0.62) | FAAHMEN1MAPK1KMT2AASAH1 | |
| SCHEMBL8492695 | 1.00 | FAAH (0.62) | FAAHMEN1MAPK1KMT2AASAH1 | |
| SCHEMBL2914509 | 1.00 | FAAH (0.62) | FAAHMEN1MAPK1KMT2AASAH1 | |
| SCHEMBL1498601 | 1.00 | FAAH (0.62) | FAAHMEN1MAPK1KMT2AASAH1 | |
| SCHEMBL1498742 | 1.00 | FAAH (0.62) | FAAHMEN1MAPK1KMT2AASAH1 | |
| SCHEMBL23521368 | 1.00 | FAAH (0.62) | FAAHMEN1MAPK1KMT2AASAH1 | |
| SCHEMBL8341797 | 1.00 | FAAH (0.62) | FAAHMEN1MAPK1KMT2AASAH1 | |
| SCHEMBL11513011 | 1.00 | FAAH (0.62) | FAAHMEN1MAPK1KMT2AASAH1 | |
| SCHEMBL1498841 | 1.00 | FAAH (0.62) | FAAHMEN1MAPK1KMT2AASAH1 | |
| SCHEMBL365322 | 1.00 | FAAH (0.62) | FAAHMEN1MAPK1KMT2AASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270496-A1 | Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | EPITECH GROUP S.R.L. (IT) | 2007-11-22 | — | — | US | claimed |
| EP-1844784-A1 | A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | Epitech Group S.r.l. (IT) | 2007-10-17 | — | — | EP | claimed |
| EP-0886551-B1 | STABILITY CONTROL AGENT COMPOSITION FOR POLYOLEFIN FOAM | KNAUS DENNIS A (US) | 2004-08-04 | — | — | EP | claimed |
| US-4039562-A | MALEIC ANHYDRIDE, FATTY ALCOHOL, ALKALI METAL SULFITE | REWO CHEMISCHE WERKE G.M.B.H. (DT) | 1977-08-02 | — | — | US | claimed |
| US-12516147-B2 | Aldimines and uses thereof | BOSTIK SA (FR) | 2026-01-06 | — | — | US | disclosed |
| EP-4077273-B1 | ALDIMINES AND USES THEREOF | BOSTIK SA (FR) | 2025-04-02 | — | — | EP | disclosed |
| WO-2024090354-A1 | AQUEOUS POLYMER EMULSION FOR COSMETIC, METHOD FOR PRODUCING SAME, AND COSMETIC | 東亞合成株式会社 | 2024-05-02 | — | — | WO | disclosed |
| WO-2024090355-A1 | AQUEOUS POLYMER EMULSION FOR COSMETIC, PRODUCTION METHOD THEREFOR, AND COSMETIC | 東亞合成株式会社 | 2024-05-02 | — | — | WO | disclosed |
| EP-4170026-A1 | MICROBIAL PRODUCTION OF ALKANOLAMIDES AND AMIDOAMINES AND USES THEREOF | Genomatica, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2023033127-A1 | EMULSION COMPOSITION, AND SKIN TOPICAL AGENT AND COSMETIC CONTAINING SAID COMPOSITION | 富士フイルム和光純薬株式会社 | 2023-03-09 | — | — | WO | disclosed |
| US-20230038642-A1 | ALDIMINES AND USES THEREOF | BOSTIK SA (FR) | 2023-02-09 | — | — | US | disclosed |
| WO-2022270640-A2 | POLYMER COMPOUND, COSMETIC, AND THICKENER | 富士フイルム和光純薬株式会社 | 2022-12-29 | — | — | WO | disclosed |
| US-4980086-A | COMPRISING A CYANOACRYLATE ESTER, ELECTROCONDUCTIVE POWDER, THERMOCONDUCTIVE POWDER, ELECTRON ACCEPTOR OR A COORDINATION COMPLEX AND ELECTRON DONOR; ADHESIVE, COATIG, PAINT, POTTING | TOAGOSEI CHEMICAL INDUSTRY, CO., LTD. (JP) | 1990-12-25 | — | — | US | disclosed |
| US-RE31744-E | Expanded olefin polymer | ASAHI-DOW LIMITED (JP) | 1984-11-20 | — | — | US | disclosed |
| EP-0001791-B1 | EXPANDABLE OLEFIN POLYMER COMPOSITION, EXPANDED PRODUCTS MADE THEREFROM AND METHOD OF MAKING THE EXPANDED PRODUCTS | THE DOW CHEMICAL COMPANY (US) | 1983-09-28 | — | — | EP | disclosed |
| US-4343913-A | AMIDE OR ESTER ADDITIVE TO PREVENT SHRINKAGE | ASAHI-DOW LIMITED (JP) | 1982-08-10 | — | — | US | disclosed |
| US-4252656-A | AEROSOL CONTAINING CATIONIC POLYMER, SOFTENING AND FOAMING AGENTS, STABILIZER, HUMECTANT, WATER, AND PROPELLANT; LAUNDRY DRIERS | COLGATE-PALMOLIVE COMPANY (US) | 1981-02-24 | — | — | US | disclosed |
| US-4214054-A | Expanded olefin polymer | ASAHI-DOW LIMITED (JP) | 1980-07-22 | — | — | US | disclosed |
| EP-0001791-A2 | Expandable olefin polymer composition, expanded products made therefrom and method of making the expanded products | THE DOW CHEMICAL COMPANY (US) | 1979-05-16 | — | — | EP | disclosed |
| US-4039562-A | MALEIC ANHYDRIDE, FATTY ALCOHOL, ALKALI METAL SULFITE | REWO CHEMISCHE WERKE G.M.B.H. (DT) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270496-A1 | Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | HCAR2, HCAR1, MYD88 | FAAH 329/4885MEN1 1658/4885MAPK1 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.